multiple myeloma

Conference Coverage
BME Signatures at Baseline and During Treatment Enable Risk Stratifications of Patients With Multiple Myeloma
12/12/2022
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
In a presentation at the 64th...
12/12/2022
Journal of Clinical Pathways
Case Report
Acupuncture-exacerbated Pyoderma Gangrenosum Associated With IgG Multiple Myeloma
11/14/2022
​​The authors present a case of a 49-year-old female who presented with pyoderma gangrenosum triggered by unregulated acupuncture treatment.
​​The authors present a case of a 49-year-old female who presented with pyoderma gangrenosum triggered by unregulated acupuncture treatment.
​​The authors present a case of...
11/14/2022
Wounds
dr nishihori
Videos
Taiga Nishihori, MD, Discusses Ixazomib Therapy After AlloHCT for High-Risk MM
06/04/2021
Taiga Nishihori, MD, shares findings from a trial of ixazomib maintenance after alloHCT in patients with high-risk MM. These data were presented at the 2021 ASCO Annual Meeting.
Taiga Nishihori, MD, shares findings from a trial of ixazomib maintenance after alloHCT in patients with high-risk MM. These data were presented at the 2021 ASCO Annual Meeting.
Taiga Nishihori, MD, shares...
06/04/2021
Oncology
All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care
Videos
All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care
03/05/2021
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO,...
03/05/2021
Journal of Clinical Pathways
HCRU and Costs Associated With CAR-T Therapy Toxicity Management in MM
Videos
HCRU and Costs Associated With CAR-T Therapy Toxicity Management in MM
12/08/2020
12/08/2020
Journal of Clinical Pathways
Adding Daratumumab to Pomalidomide and Dexamethasone Improves PFS in Relapsed/Refractory MM
Videos
Adding Daratumumab to Pomalidomide and Dexamethasone Improves PFS in Relapsed/Refractory MM
12/04/2020
12/04/2020
Journal of Clinical Pathways
News
Treatment Algorithms for Newly Diagnosed and Relapsed Multiple Myeloma
12/02/2020
12/02/2020
Journal of Clinical Pathways
Care Coordination Between Prescribers and the Specialty Pharmacy for Multiple Myeloma: Qualitative Insights Into Designing a Quality Improvement Program for Multisite Community Oncology Practices
From the Field
Care Coordination Between Prescribers and the Specialty Pharmacy for Multiple Myeloma: Qualitative Insights Into Designing a Quality Improvement Program for Multisite Community Oncology Practices
08/19/2020
Abstract: It is widely recognized that the quality of medical care received in the United States is suboptimal, and poor-quality care may contribute to disparities in cancer incidence and mortality. While...
Abstract: It is widely recognized that the quality of medical care received in the United States is suboptimal, and poor-quality care may contribute to disparities in cancer incidence and mortality. While...
...
08/19/2020
Journal of Clinical Pathways
Research in Review
Myeloma Treatment Patterns Vary Among European Practices
07/11/2016
JCP Editors
  There is significant variation in how European practices treat patients with multiple myeloma, according to a cross-sectional study published in the British Journal of Haematology. For the study,...
  There is significant variation in how European practices treat patients with multiple myeloma, according to a cross-sectional study published in the British Journal of Haematology. For the study,...
...
07/11/2016
Journal of Clinical Pathways
Daratumumab More Cost Effective for Multiple Myeloma Treatment
06/13/2016
JCP Editors
Daratumumab may be the most cost-effective treatment option for patients with multiple myeloma (MM) compared with other novel therapies, according to a poster presented at the 2016 American Society of Clinical...
Daratumumab may be the most cost-effective treatment option for patients with multiple myeloma (MM) compared with other novel therapies, according to a poster presented at the 2016 American Society of Clinical...
...
06/13/2016
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use